Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View

IBD 50

Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View

Licensing

Kiniksa Pharmaceuticals International (KNSA) on Tuesday was extending a win streak and moving closer to a buy zone, with investors seeking stakes in the IBD 50 biotech stock that's projecting near-blockbuster sales status for its key product. The company focuses on treatments for rare diseases, particularly cardiovascular conditions. The biotech is profitable, a key achievement in an industry well-known for…